| Jennifer Jo Warren, APRN | |
|
1700 Sw 7th St, Topeka, KS 66606-2489 | |
| (785) 295-5310 | |
| Not Available |
| Full Name | Jennifer Jo Warren |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 1700 Sw 7th St, Topeka, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821659061 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 53-78844-102 (Kansas) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 53-78844-102 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holton Community Hospital | Holton, KS | Hospital |
| Rooks County Health Center | Plainville, KS | Hospital |
| Hiawatha Community Hospital | Hiawatha, KS | Hospital |
| Ellsworth County Medical Center | Ellsworth, KS | Hospital |
| Community Medical Center, Inc. | Falls city, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rooks County Health Center | 8325959331 | 22 |
| Rural Health Resources Of Jackson Co Inc | 7810807690 | 20 |
| White Cloud Health Center Llc | 9830437995 | 5 |
News Archive
According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.
The issue of global food security is a problem for us now, and for future generations. Perhaps the most visible issue is malnutrition, which affects millions in the developing world and poses a risk to many vulnerable people in the developed world.
Researchers at the Department of Integrative Biomedical Sciences, University of Cape Town, South Africa, found evidence of a significant change in the selective forces acting on immunologically important SARS-CoV-2 genes, such as N and S. These likely coincided with the emergence of the 501Y lineages.
Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.
A potentially disturbing new study suggests that SARS-CoV-2 may be undergoing strategic mutations that affect the host immune capacity to recognize and combat the pathogen via T effector cells.
› Verified 1 days ago
| Entity Name | Rural Health Resources Of Jackson Co Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235238296 PECOS PAC ID: 7810807690 Enrollment ID: O20031111000573 |
News Archive
According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.
The issue of global food security is a problem for us now, and for future generations. Perhaps the most visible issue is malnutrition, which affects millions in the developing world and poses a risk to many vulnerable people in the developed world.
Researchers at the Department of Integrative Biomedical Sciences, University of Cape Town, South Africa, found evidence of a significant change in the selective forces acting on immunologically important SARS-CoV-2 genes, such as N and S. These likely coincided with the emergence of the 501Y lineages.
Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.
A potentially disturbing new study suggests that SARS-CoV-2 may be undergoing strategic mutations that affect the host immune capacity to recognize and combat the pathogen via T effector cells.
› Verified 1 days ago
| Entity Name | Ellsworth County Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972504546 PECOS PAC ID: 5395643357 Enrollment ID: O20040716000216 |
News Archive
According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.
The issue of global food security is a problem for us now, and for future generations. Perhaps the most visible issue is malnutrition, which affects millions in the developing world and poses a risk to many vulnerable people in the developed world.
Researchers at the Department of Integrative Biomedical Sciences, University of Cape Town, South Africa, found evidence of a significant change in the selective forces acting on immunologically important SARS-CoV-2 genes, such as N and S. These likely coincided with the emergence of the 501Y lineages.
Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.
A potentially disturbing new study suggests that SARS-CoV-2 may be undergoing strategic mutations that affect the host immune capacity to recognize and combat the pathogen via T effector cells.
› Verified 1 days ago
| Entity Name | Rural Health Resources Of Jackson Co Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1902805716 PECOS PAC ID: 7810807690 Enrollment ID: O20061104000231 |
News Archive
According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.
The issue of global food security is a problem for us now, and for future generations. Perhaps the most visible issue is malnutrition, which affects millions in the developing world and poses a risk to many vulnerable people in the developed world.
Researchers at the Department of Integrative Biomedical Sciences, University of Cape Town, South Africa, found evidence of a significant change in the selective forces acting on immunologically important SARS-CoV-2 genes, such as N and S. These likely coincided with the emergence of the 501Y lineages.
Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.
A potentially disturbing new study suggests that SARS-CoV-2 may be undergoing strategic mutations that affect the host immune capacity to recognize and combat the pathogen via T effector cells.
› Verified 1 days ago
| Entity Name | Rooks County Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841570298 PECOS PAC ID: 8325959331 Enrollment ID: O20111025000737 |
News Archive
According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.
The issue of global food security is a problem for us now, and for future generations. Perhaps the most visible issue is malnutrition, which affects millions in the developing world and poses a risk to many vulnerable people in the developed world.
Researchers at the Department of Integrative Biomedical Sciences, University of Cape Town, South Africa, found evidence of a significant change in the selective forces acting on immunologically important SARS-CoV-2 genes, such as N and S. These likely coincided with the emergence of the 501Y lineages.
Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.
A potentially disturbing new study suggests that SARS-CoV-2 may be undergoing strategic mutations that affect the host immune capacity to recognize and combat the pathogen via T effector cells.
› Verified 1 days ago
| Entity Name | Topeka Physician Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770008849 PECOS PAC ID: 6406112473 Enrollment ID: O20171107002163 |
News Archive
According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.
The issue of global food security is a problem for us now, and for future generations. Perhaps the most visible issue is malnutrition, which affects millions in the developing world and poses a risk to many vulnerable people in the developed world.
Researchers at the Department of Integrative Biomedical Sciences, University of Cape Town, South Africa, found evidence of a significant change in the selective forces acting on immunologically important SARS-CoV-2 genes, such as N and S. These likely coincided with the emergence of the 501Y lineages.
Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.
A potentially disturbing new study suggests that SARS-CoV-2 may be undergoing strategic mutations that affect the host immune capacity to recognize and combat the pathogen via T effector cells.
› Verified 1 days ago
| Entity Name | Minor Med Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093827511 PECOS PAC ID: 6709897580 Enrollment ID: O20190912001027 |
News Archive
According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.
The issue of global food security is a problem for us now, and for future generations. Perhaps the most visible issue is malnutrition, which affects millions in the developing world and poses a risk to many vulnerable people in the developed world.
Researchers at the Department of Integrative Biomedical Sciences, University of Cape Town, South Africa, found evidence of a significant change in the selective forces acting on immunologically important SARS-CoV-2 genes, such as N and S. These likely coincided with the emergence of the 501Y lineages.
Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.
A potentially disturbing new study suggests that SARS-CoV-2 may be undergoing strategic mutations that affect the host immune capacity to recognize and combat the pathogen via T effector cells.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Jo Warren, APRN 600 Sw Jewell Ave, Topeka, KS 66606-1607 Ph: (785) 295-5310 | Jennifer Jo Warren, APRN 1700 Sw 7th St, Topeka, KS 66606-2489 Ph: (785) 295-5310 |
News Archive
According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.
The issue of global food security is a problem for us now, and for future generations. Perhaps the most visible issue is malnutrition, which affects millions in the developing world and poses a risk to many vulnerable people in the developed world.
Researchers at the Department of Integrative Biomedical Sciences, University of Cape Town, South Africa, found evidence of a significant change in the selective forces acting on immunologically important SARS-CoV-2 genes, such as N and S. These likely coincided with the emergence of the 501Y lineages.
Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.
A potentially disturbing new study suggests that SARS-CoV-2 may be undergoing strategic mutations that affect the host immune capacity to recognize and combat the pathogen via T effector cells.
› Verified 1 days ago